Merck Serono GmbH, Darmstadt, Germany
Darmstadt, 64289, Germany
NCT Number: NCT01075711
Rheumatoid arthritis is the most common rheumatic disease with symptomatic morning stiffness which entails a quite essential restriction in the everyday life and in the life quality. This observational, uncontrolled, multicentric study is aimed to assess the improvement in the activity status or QoL of subjects with RA being treated with the Tempus tablet.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Darmstadt, 64289, Germany
Rheumatoid arthritis is characterised with a sudden onset , with pains in the little finger or toe joints, progressively affecting various joints and symptomatic morning stiffness. For subjects with RA, morning stiffness entails a quite essential restriction in the everyday life and in the life quality. This observational, uncontrolled, multicentric study is aimed to assess the improvement in the activity status or QoL of subjects with RA being treated with the Tempus tablet. A total of 8,000 subjects with diagnosed, active RA will be included in the study The study will apply to 2 target groups: general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months; and specialists (rheumatologist) with an observation period of 9 months. Three subjects are expected per in-house doctor and 10 subjects per rheumatologist.
OBJECTIVES
Primary Objective:
Secondary Objectives:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
According to SPC
Other names: Lodotra
Time frame: Beginning of the examination (gross-root survey) and after 3 months (follow-up)
Time frame: Beginning until after 9 months
Time frame: Beginning until after 9 months
Time frame: Beginning until after 9 months
Time frame: Beginning until after 9 months
Time frame: Beginning until after 9 months
Time frame: Beginning until after 9 months
Merck KGaA, Darmstadt, Germany
Industry
Non-interventional Study for Determining the Improvement in the Activity Status / Life Quality of Patients With Rheumatoid Arthritis Being Treated With the Tempus Tablet
Acronym: LODOTRA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04196868
Arthritis, Arthritis, Rheumatoid
Bayonne, France
View Trial DetailsNCT02615951
Arthritis, Arthritis, Rheumatoid
Montpellier, Hérault, France
View Trial DetailsNCT05961267
Ankylosis, Arthritis
Bordeaux, France
View Trial DetailsNCT06276387
Arthritis, Arthritis, Rheumatoid
San Francisco, California, United States
View Trial Details